|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.700 USD | +2.66% |
|
+4.65% | -89.31% |
| 25/06 | Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment | MT |
| 11/06 | Jaguar Health Establishes First Site for Canalevia-CA1 Field Study | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability (Composite) | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
| 34.83L | - | - | - | |||
| 71TCr | ||||||
| 38TCr | ||||||
| 34TCr | ||||||
| 32TCr | ||||||
| 26TCr |
- Stock Market
- Equities
- JAGX Stock
- Charts Jaguar Health, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition